Navigation Links
FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
Date:3/28/2011

by change in sphere and cylinder of < 0.5 D.

Brief profile Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology suppliers. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiation therapy. In the 2009/2010 (30 September) financial year, around 2,200 employees generated revenue of EUR 676 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. Thirty-five percent of Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and opto-electronics industry. Carl Zeiss offers innovative solutions for the future-oriented markets Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. In financial year 2009/2010, the Group generated revenue of around EUR 2.98 billion. From financial year 2010/2011 onwards, eyeglass lens manufacturer Carl Zeiss Vision shall be integrated as an autonomous business group (revenue of around EUR 880 million in financial year 2009/2010). The Carl Zeiss Group thus employs a workforce of around 24,000 worldwide, more than 10,000 of whom are based in Germany. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For further information see: http://www.medit
'/>"/>

SOURCE Carl Zeiss Meditec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... -- In a sweeping analysis assessing the current state of ... researchers conclude that there remains considerable room for improving ... groups, but especially for adolescents and young adults. The ... underscoring the need to address barriers to care and ... 1 patients achieve optimal metabolic control. ...
(Date:5/21/2015)... 21, 2015  When Ryan Rendino first ... of his neck, he figured it was ... weeks off from weight lifting. ... A series of doctor ... to Michel Kliot, MD , a ...
(Date:5/21/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that on ... company,s vice president of operations, was granted an option to ... per share exercise price of $0.43, the closing trading price ... to Cardica, Inc.,s Inducement Plan, which was approved by the ... of the Nasdaq Global Market for equity grants to induce ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4Cardica Announces New Employment Inducement Grant 2
... DURECT Corporation,(Nasdaq: DRRX ) announced today ... accepted the New Drug Application (NDA) of REMOXY(R) ... Review to drug,candidates that have the potential to ... goal for completing review of a drug,with Priority ...
... Receive Milestone Payment from MedImmune, PRINCETON, N.J., ... announced today that its partner MedImmune, Inc. has,initiated ... for the,potential treatment of systemic lupus erythematosus (SLE ... by Medarex,s UltiMAb Human,Antibody Development System(R). Under the ...
Cached Medicine Technology:REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted 2REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted 3Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 3Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 4
(Date:5/22/2015)... WA (PRWEB) May 22, 2015 According to ... of all generations are equally as likely to worry about ... Millennials, 75% Gen X, 77% Boomers, 69% Silent Generation), which ... agree they are scared of aging, particularly Millennials (47%), Gen ... by Harris Poll in April, 2015 among more than 2,000 ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 The ... Plaza Dental announces that they are now offering ... and other dental treatments. At consultations, patients can ... Questions regarding what certain treatments can achieve and ... covered during this initial appointment. If treatments are ...
(Date:5/22/2015)... 2015 Wimbledon Health Partners, the leading ... echocardiogram and NCV testing , is proud to ... All American National athlete, to the Wimbledon Athletics division. ... high level of testing and information it provides to ... athletic trainers, this way they can focus on the ...
(Date:5/22/2015)... Houston, Texas (PRWEB) May 22, 2015 ... Denver, Colorado. In the past 9 years they have ... across the United States and Canada. Because of this ... they have established corporate offices in Denver, Colorado, Cleveland, ... Veatch Consulting specializes in opening new dental offices, dental ...
(Date:5/22/2015)... 2015 In efforts to offer full ... containing particular muscles stretches has been a large focus ... stretches now complete, Chunk Fitness envisions a mid-June launch ... filmed and released at a later point in time. ... http://www.chunkfitness.com/stretches . , About the Company: Chunk Fitness ...
Breaking Medicine News(10 mins):Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3
... 15, 2009 Avalon Laboratories, LLC (Avalon) today announced it ... Administration (FDA) and CE Mark acceptance from the European Union ... systems. The clearances enable Avalon to begin distributing these products ... and the European Union. The company also was issued ...
... a leading,innovator of physiological monitoring solutions, has been ... 2009 award for the Onyx(R) II, Model 9560,fingertip ... oximeter,the innovative device combines Bluetooth(R) wireless technology with ... accurately,monitor vital signs. , ...
... Heartland Dental Care, Inc.,acquired four dental practices and ... 2008. , The four ... in Springfield, Va., and two practices in McKinney, ... include locations in,Hendersonville, Tenn., Sycamore, Ill., and Liberty ...
... homes, seniors increasingly turning to home care vs. assisted ... estate crisis has affected all aspects of life, and ... unable to sell their homes, moving to an assisted ... reason, the option of aging-in-place with retrofits is growing ...
... policy and government relations firms to provide integrated services ... WashingtonWASHINGTON, Jan. 15 EBG Advisors, Inc. and Oldaker ... Advisors, LLC, a strategic alliance of the public policy ... care law firms, and a leading government relations firm. ...
... may lead to blood clots, study says , , THURSDAY, ... pills don,t seem to increase the risk of heart disease ... , But more research on the newer generations of ... especially true because more women over age 35 are taking ...
Cached Medicine News:Health News:Avalon Laboratories receives FDA and European clearances to market three catheter devices 2Health News:Nonin Medical's Onyx(R) II, Model 9560 Receives Bluetooth SIG's Best of CES 2009 Award 2Health News:Heartland Dental Care, Inc. Adds Seven Dental Practices in Fourth Quarter 2008 2Health News:Housing Crisis Affects Seniors Needing Care 2Health News:Housing Crisis Affects Seniors Needing Care 3Health News:EBG Advisors and Oldaker Group Form National Health Advisors 2Health News:Newer Contraceptives Don't Increase Heart Risk 2Health News:Newer Contraceptives Don't Increase Heart Risk 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: